A Gigout1, H Guehring2, D Froemel3, A Meurer4, C Ladel5, D Reker6, A C Bay-Jensen7, M A Karsdal8, S Lindemann9. 1. Osteoarthritis Research, Merck KGaA, Darmstadt, Germany. Electronic address: anne.gigout@merckgroup.com. 2. Osteoarthritis Research, Merck KGaA, Darmstadt, Germany. Electronic address: hans.guehring@merckgroup.com. 3. Orthopaedic University Hospital Friedrichsheim, Frankfurt, Germany. Electronic address: Dara.Froemel@friedrichsheim.de. 4. Orthopaedic University Hospital Friedrichsheim, Frankfurt, Germany. Electronic address: Andrea.Meurer@friedrichsheim.de. 5. Osteoarthritis Research, Merck KGaA, Darmstadt, Germany. Electronic address: christoph.ladel@merckgroup.com. 6. Rheumatology, Biomarkers and Research, Nordic Bioscience, Herlev, Denmark. Electronic address: dre@Nordicbioscience.com. 7. Rheumatology, Biomarkers and Research, Nordic Bioscience, Herlev, Denmark. Electronic address: acbj@Nordicbioscience.com. 8. Rheumatology, Biomarkers and Research, Nordic Bioscience, Herlev, Denmark. Electronic address: mk@NordicBio.com. 9. Osteoarthritis Research, Merck KGaA, Darmstadt, Germany. Electronic address: Sven.Lindemann@merckgroup.com.
Abstract
OBJECTIVE: Fibroblast growth factor (FGF) 18 has been shown to increase cartilage volume when injected intra-articularly in animal models of osteoarthritis (OA) and in patients with knee OA (during clinical development of the recombinant human FGF18, sprifermin). However, the exact nature of this effect is still unknown. In this study, we aimed to investigate the effects of sprifermin at the cellular level. DESIGN: A combination of different chondrocyte culture systems was used and the effects of sprifermin on proliferation, the phenotype and matrix production were evaluated. The involvement of MAPKs in sprifermin signalling was also studied. RESULTS: In monolayer, we observed that sprifermin promoted a round cell morphology and stimulated both cellular proliferation and Sox9 expression while strongly decreasing type I collagen expression. In 3D culture, sprifermin increased the number of matrix-producing chondrocytes, improved the type II:I collagen ratio and enabled human OA chondrocytes to produce a hyaline extracellular matrix (ECM). Furthermore, we found that sprifermin displayed a 'hit and run' mode of action, with intermittent exposure required for the compound to fully exert its anabolic effect. Finally, sprifermin appeared to signal through activation of ERK. CONCLUSIONS: Our results indicate that intermittent exposure to sprifermin leads to expansion of hyaline cartilage-producing chondrocytes. These in vitro findings are consistent with the increased cartilage volume observed in the knees of OA patients after intra-articular injection with sprifermin in clinical studies.
OBJECTIVE:Fibroblast growth factor (FGF) 18 has been shown to increase cartilage volume when injected intra-articularly in animal models of osteoarthritis (OA) and in patients with knee OA (during clinical development of the recombinant humanFGF18, sprifermin). However, the exact nature of this effect is still unknown. In this study, we aimed to investigate the effects of sprifermin at the cellular level. DESIGN: A combination of different chondrocyte culture systems was used and the effects of sprifermin on proliferation, the phenotype and matrix production were evaluated. The involvement of MAPKs in sprifermin signalling was also studied. RESULTS: In monolayer, we observed that sprifermin promoted a round cell morphology and stimulated both cellular proliferation and Sox9 expression while strongly decreasing type I collagen expression. In 3D culture, sprifermin increased the number of matrix-producing chondrocytes, improved the type II:I collagen ratio and enabled human OA chondrocytes to produce a hyaline extracellular matrix (ECM). Furthermore, we found that sprifermin displayed a 'hit and run' mode of action, with intermittent exposure required for the compound to fully exert its anabolic effect. Finally, sprifermin appeared to signal through activation of ERK. CONCLUSIONS: Our results indicate that intermittent exposure to sprifermin leads to expansion of hyaline cartilage-producing chondrocytes. These in vitro findings are consistent with the increased cartilage volume observed in the knees of OA patients after intra-articular injection with sprifermin in clinical studies.
Authors: G R Meloni; A Farran; B Mohanraj; H Guehring; R Cocca; E Rabut; R L Mauck; G R Dodge Journal: Eur Cell Mater Date: 2019-08-08 Impact factor: 3.942
Authors: Jason S Kim; Silvana Borges; Daniel J Clauw; Philip G Conaghan; David T Felson; Thomas R Fleming; Rachel Glaser; Elizabeth Hart; Marc Hochberg; Yura Kim; Virginia B Kraus; Larissa Lapteva; Xiaojuan Li; Sharmila Majumdar; Timothy E McAlindon; Ali Mobasheri; Tuhina Neogi; Frank W Roemer; Rebecca Rothwell; Robert Shibuya; Jeffrey Siegel; Lee S Simon; Kurt P Spindler; Nikolay P Nikolov Journal: Semin Arthritis Rheum Date: 2022-07-14 Impact factor: 5.431
Authors: Brett C Geiger; Sheryl Wang; Robert F Padera; Alan J Grodzinsky; Paula T Hammond Journal: Sci Transl Med Date: 2018-11-28 Impact factor: 17.956
Authors: Mackenzie L Sennett; Gregory R Meloni; Alexandra J E Farran; Hans Guehring; Robert L Mauck; George R Dodge Journal: J Orthop Res Date: 2018-07-26 Impact factor: 3.494
Authors: Ditte Reker; Cecilie F Kjelgaard-Petersen; Anne Sofie Siebuhr; Martin Michaelis; Anne Gigout; Morten A Karsdal; Christoph Ladel; Anne C Bay-Jensen Journal: J Transl Med Date: 2017-12-12 Impact factor: 5.531
Authors: Yunyun Luo; Yi He; Ditte Reker; Natasja Stæhr Gudmann; Kim Henriksen; Ole Simonsen; Christoph Ladel; Martin Michaelis; Ali Mobasheri; Morten Karsdal; Anne-Christine Bay-Jensen Journal: Int J Mol Sci Date: 2018-11-06 Impact factor: 5.923
Authors: Honey Hendesi; Suzanne Stewart; Michelle L Gibison; Hans Guehring; Dean W Richardson; George R Dodge Journal: J Orthop Res Date: 2021-05-12 Impact factor: 3.102